Opendata, web and dolomites

Everfill

Improving the Quality of Life of Millions through the Revolutionary Approach in Dermal Regeneration Care

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Everfill project word cloud

Explore the words cloud of the Everfill project. It provides you a very rough idea of what is the project "Everfill" about.

human    oy    superior    half    massive    diseases    estimate    tissues    everyday    commercial    first    dressings    revenues    revenue    round    patient    gaining    incurable    body    ipr    tampere    triggers    wound    diabetes    necrosis    allogeneic    gels    university    savings    business    bioengineered    classification    launch    sme    patented    trials    defects    quality    2019    regeneration    health    people    healing    regenerate    normal    off    outcomes    initial    ongoing    everfill    countries    feasibility    wounds    building    care    revolutionize    populations    venture    batch    lifestyle    spin    thorough    unhealthy    invested    combination    350    damaged    sedative    scientific    global    bioactive    extracted    dimensions    reg    contains    21    proof    faster    severe    sales    uses    clinical    tissue    trigger    life    instrument    millions    amputations    ageing    curing    tolerated    diet    investors    safe    million    capital    occurrence    conducting    distorts    commercialization    leg    regulatory    deep    material    experimental   

Project "Everfill" data sheet

The following table provides information about the project.

Coordinator
EVERFILL OY 

Organization address
address: FREDRIKINKATU 25 A 17
city: HELSINKI
postcode: 120
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Project website http://www.everfill.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EVERFILL OY FI (HELSINKI) coordinator 50˙000.00

Map

 Project objective

The combination of ageing populations, sedative lifestyle and unhealthy diet results in increase in such diseases as diabetes. One of the outcomes of diabetes is the occurrence of very severe and deep leg wounds. As diabetes distorts the body’s normal tissue regeneration processes, it often results in necrosis and amputations, which are still everyday practice even in developed countries. Everfill Oy is a university spin-off that has developed Everfill®, a patented allogeneic bioengineered product that will revolutionize the care of wounds. Everfill® uses extracted human bioactive growth factors that trigger the patient’s body to regenerate damaged tissues. This results in faster and more thorough healing. As Everfill® contains only human material and triggers the patient to regenerate own tissue, it is a superior product for dressings and wound gels. It is safe and well tolerated and has no side effects. Everfill® will enable curing currently incurable tissue defects and wounds, achieve massive savings in health care, and improve the quality of life for millions of people. Our estimate of its global revenue potential is over €350 million per year. So far €0.7 million were invested into the scientific research conducted at the University of Tampere and related to Everfill® product. In order to launch the product commercialization phase, we are looking for €5 million funding for 2019-21, of which half from venture capital investors within the ongoing round A and another half from the SME Instrument. This funding will be used for gaining EU and US regulatory classification for the product, building up business process proof of concept to produce the product for clinical trials, and conducting the first phase of clinical trials in EU. Initial sales revenues from experimental patient care using the first batch of product will be generated during the project. Our SME-1 feasibility study will have IPR, legal, commercial and operational feasibility dimensions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EVERFILL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EVERFILL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More